Nasdaq9d
Vaxcyte Advances VAX-31 Infant Study to Stage 2 Following Positive Stage 1 Safety Data
Vaxcyte, Inc. announced that it has progressed to Stage 2 of its Phase 2 infant study for the VAX-31 pneumococcal conjugate vaccine after a review of Stage 1 safety and tolerability data.
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...
Yahoo Finance8d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte co-founder and CEO Grant Pickering said: “Advancing to stage two of the VAX-31 infant Phase II study represents a significant step forward in evaluating the broadest vaccine candidate in ...
Investing9d
Vaxcyte advances to final stage in infant vaccine study
the study has progressed to Stage 2, where the vaccine's safety, tolerability, and immunogenicity will be further evaluated in healthy infants. VAX-31 is designed to provide broad coverage against ...